ArticleHepatology international2024
Telomere length and mortality in lean MAFLD: the other face of metabolic adaptation.
Article in Hepatology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis.Hepatology international · 2025Pooled it
- The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease.Hepatology international · 2025Guideline
- Hepatocyte senescence in metabolic dysfunction-associated steatotic liver disease (MASLD).Hepatology communications · 2026Review
- Differential DNAm-GDF15 and mitochondrial profile in lean MAFLD.Clinical and experimental medicine · 2026Article
- What is new in the 2025 APASL guidelines for metabolic dysfunction-associated fatty liver disease?Hepatobiliary surgery and nutrition · 2026Article
- Choline Deficiency Drives the Inflammation-Fibrosis Cascade: A Spatiotemporal Atlas of Hepatic Injury from Weeks 6 to 10.Antioxidants (Basel, Switzerland) · 2026Article
- MASLD versus MAFLD in lean steatotic liver disease: diagnostic overlap, inclusivity, and the metabolically healthy lean phenotype.Clinical and experimental medicine · 2025Article
- Risk factors for pulmonary function alterations in children with metabolic dysfunction-associated fatty liver disease.Scientific reports · 2025Article
- Joint association of inflammatory markers and sedentary time with mortality in metabolic dysfunction-associated steatotic liver disease population and the mediating role of inflammation.European journal of medical research · 2025Article
- Association between triglyceride glucose-body mass index and MASH, cardiovascular disease in MASLD patients: a cross-sectional study and machine learning analysis.Metabolism open · 2025Article
- Genetic insights of waist-to-height ratio on the risk of steatotic and advanced liver diseases: genome-wide association study and polygenic risk score-based analyses.Human genomics · 2025Article
- Utility of the serum alanine aminotransferase to high density lipoprotein cholesterol ratio in evaluating nonalcoholic fatty liver disease and liver fibrosis.Scientific reports · 2025Article
- Association between oxidative stress and metabolic-associated fatty liver disease in the US population.Scientific reports · 2025Article
- Risk factor analysis and predictive model construction of lean MAFLD: a cross-sectional study of a health check-up population in China.European journal of medical research · 2025Review
- Correlation analysis of the triglyceride-glucose index and related parameters in metabolic dysfunction-associated fatty liver disease.Scientific reports · 2025Article
- MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk.Hepatic medicine : evidence and research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND AND
aimsHealthy weight (lean) patients with metabolic dysfunction-associated fatty liver disease (MAFLD) have a more favorable metabolic and histological profile in cross-sectional studies compared with their non-lean counterparts. Paradoxically, they also have higher overall mortality. The underpinning pathophysiology of this paradox is not understood. Telomere attrition is associated with increased mortality in various diseases.
methodsWe investigated the role of telomere length in the pathogenesis of lean MAFLD in cohorts with biopsy-proven MAFLD (n = 303). We measured serum malondialdehyde (MDA) levels and hepatic 8-hydroxydeoxyguanosine (8-OHdG) and 4-hydroxy-2-nonenal (4-HNE) expression (reactive oxygen species (ROS) markers), growth/differentiation factor-15 (GDF-15) and tested the effect of H
resultsTelomere length was significantly lower in patients with lean MAFLD (p < 0.001). They also demonstrated an increase in ROS levels and decreases in GDF-15. H
conclusionDifferences in telomere length in part explain the increased mortality of lean compared to non-lean patients with MAFLD. The effect is in part mediated through ROS activation and provide opportunities for therapy.
Indexed as
Identifiers
38900410What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.